Loyon Lotion 15 ml

Product Information

The IMD was not to be applied together with other hair care or hair cosmetic products. All relevant medication that had been taken 6weeks prior to Day 1 and any medication, including over-the-counter remedies, that were taken during the study were regarded as concomitant treatment and had to be documented. The use of vitamin D preparations and fluorine-containing medications was allowed. Other concomitant medications were to be kept to a minimum during the study; however, if considered necessary for the subject’s welfare and unlikely to interfere with the study objectives, these were allowed at the discretion of the investigator.

LOYON® is a unique, patented combination of the dry emollient Cetiol® CC and the medical silicone oil Dimeticone. The liquid compound is very easily applied and spreads exceptionally well, due to its low surface tension. This also makes LOYON® very economical.This study suggests that LOYON(®) is well tolerated, safe and effective in facilitating the removal of scaling in infants and children with cradle cap. With its gentle approach and rapid effect, LOYON(®) thus represents a good alternative to home remedies for treatment of cradle cap. The results recorded by the investigators are in agreement with the positive treatment evaluations by the parents/legal guardians. According to the judgment by most parents/legal guardians the product is easy to apply (90% of parents/legal guardians), has a comfortable consistency (80%) and brings about a significant improvement of skin appearance (85%). 70% of them were satisfied with the improved skin appearance in their children, with 20% experiencing this as positively affecting the relationship to their child. In one subject, an unpleasant odor of the affected skin had been noted at baseline which improved with treatment. Overall treatment with the IMD was rated as ‘good’. LOYON® is a unique, patented combination of the dry emollient Cetiol® CC and the medical silicone oil Dimeticon. The liquid compound is very easily applied and spreads exceptionally well, due to its low surface tension. This also makes LOYON® very economical.

For this single-center, noninterventional clinical trial, patients with psoriasis capitis or psoriasis corporis received once-daily Loyon treatment for 7 days. The 2 target areas were psoriasis affected skin, located on the scalp or body. On day 1 (baseline), 2 target lesions were selected and documented in the case report form. For psoriasis corporis, the Psoriasis Area Severity Index (PASI) score was calculated, and for psoriasis capitis, Psoriasis Scalp Severity Index (PSSI) score was calculated. Baseline scaling scores and redness scores were calculated for the 2 target lesions of the scalp or the body on a 5-point scale each. The first treatment was applied in the study center, and patients washed off the product at home at the earliest 3 hours after application. Treatments on days 2 and 3 were performed by patients in their private setting. On day 4, patients returned to the study center for evaluation. Treatments on days 5, 6, and 7 were again done by patients. On day 8, patients returned to the study center for a final visit. 2 Loyon Psoriasis And Cradle Cap Solution removes scales with an innovative, purely physical mode of action, independent of the underlying disease. Therefore Loyon is effective against different types of skin diseases, such as psoriasis or cradle cap. Male or female infants/children aged 3–36months with clinically diagnosed cradle cap on the scalp and a scaling score of at least 2 on a 5-point scale from 0 to 3 (0, 0.5, 1, 2 and 3) were eligible for the study. For study inclusion, the physical examination of the scalp had to be without abnormal findings, unless the investigator considered an abnormality irrelevant to the outcome of the study. Subjects were excluded from this study, if they experienced symptoms of a clinically significant illness with potential influence on the outcome of the study within 4weeks prior to or during the study, if they suffered from inflammation, tinea capitis or psoriasis capitis, if they used dimethicone containing shampoos and/or if they participated in another clinical trial within 4weeks prior to or during the study. Further exclusion criteria were known hypersensitivity to components of the study preparation and treatment within 4weeks prior to or during the study with systemically or locally acting drugs such as steroids, antimycotics, salicylic acid or other keratolytics, or skin care products such as olive oil with potential influence on the outcome of the study. The use of baby shampoos was allowed within 4weeks prior to the study.

Loyon Cradle Cap Instructions

Treatment prevents scratching and therefore injury to the skin and infection that can result from bleeding. To evaluate the safety and efficacy of topically applied, nonmedicated Loyon in facilitating the removal of scaling in infants and children with cradle cap without inducing spot bleedings. 1